Neutralization susceptibility of B subtype variant B' primary HIV- 1 isolates

Scandinavian Journal of Immunology

Volumn 47, Issue 6, 1998, Pages 603-608

  Bongertz, V ^a   Costa, C I ^a   Guimaraes M L ^a   Grinsztejn, B ^b   Joao Filho E C ^c   Galvao Castro B ^a   Morgado, M G ^a   Santos, V G V ^b   Rolla, V C ^b   Cavalcante, S ^b   Galhardo, M C G ^b   Guimaraes M R C ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c Servidores Do Estado Hospital   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAZIL; CROSS REACTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS CHARACTERIZATION; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

ANTIGENIC VARIATION; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; HUMANS; NEUTRALIZATION TESTS;

EID: 7144257188     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1998.00345.x     Document Type: Article

References (33)

1. Potts KE, Kalish ML, Lott T et al. Genetic heterogeneity of the V3 region of the HIV-1 envelope glycoprotein in Brazil. AIDS 1993;7:1191-7.
2. Morgado MG, Sabino E, Shpear EG et al. V3 region polymorphism in HIV-1 from Brazil: prevalence of subtype B strains divergent from the North American/European prototype and detection of subtype F. AIDS Res Human Retroviruses 1994;10:569-75.
3. WHO Network for HIV Isolation and Characterization. HIV Type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. AIDS Res Human Retroviruses 1994;10:1327-43.
4. Sabino E, Shpear E, Morgado M et al. Identification of an HIV-1 proviral genome recombinant between subtype B and F in PBMCs obtained from an individual in Brazil. J Virol 1994;68:6340-6.
5. Gao F, Morrison SG, Robertson DL et al. Molecular cloning and analysis of functional envelope genes from Human Immunodeficiency Virus Type 1 sequence subtypes A through G. J Virol 1996;70:1651-67.
6. Galvão-Castro B, Couto-Fernandes JC, Mello MA et al. A nationwide effort to systematically monitor HIV-1 diversity in Brazil. Mem Inst Oswaldo Cruz 1996;91:335-8.
7. Hammer S. Advances in antiretroviral therapy and viral load monitoring. XI Intl Conf AIDS, Transcontinental Printing Inc., Vancouver, Canada, Mo01, 1996.
8. Wain-Hobson S. Down or out in blood and lymph? Nature 1997;387:123-4.
9. Poignard P, Klasse PJ, Sattentau QJ. Antibody neutralization of HIV-1. Immunology Today 1996;7:239-47.
10. Lathey JL, Pratt RD, Spector SA. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with HIV-1. J Inf Dis 1997; 175:231-3.
11. Bollinger RC, Egan MA, Chun TW, Mathieson B, Siliciano RF. Cellular immune responses to HIV-1 in progressive and non-progressive infections. AIDS 1996;10:S85-96.
12. Nyambi PN, Nkengason GJ, Lewi P et al. Multivariate analysis of Human Immunodeficiency Virus Type 1 neutralization data. J Virol 1996;70:6235-43.
13. Trkola A, Pomales AB, Yuan H, et al. Cross-clade neutralization of primary isolates of Human Immunodeficiency Virus Type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-17.
14. Kostrikis LG, Michalopoulou Z-H, Cao Y, Moore JP, Ho DD. Determining neutralization serotypes of HIV-1 by neural networks. AIDS Res Hum Retrovirus 1996;12:1667-9.
15. Moore J, Trkola A. HIV Type 1 coreceptors, neutralization serotypes, and vaccine development. AIDS Res Hum Retrovirus 1997;13:733-6.
16. Centers for Disease Control. Classification system for human T-lymphotropic virus type III/lymphoadenopathy associated virus infections. Ann Int Med 1986;105:234-7.
17. Ruebsamen-Waigmann H, von Briesen H, Holmes H et al. Standard conditions of virus isolation reveal biological variability of HIV type 1 in different regions of the world. AIDS Res Hum Retroviruses 1994;10:1401-8.
18. Albert J, Abrahamson B, Nagy K et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990;4:107-12.
19. Bongertz V, Costa CI, Santos VGV et al. Correlation between susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies. AIDS 1997;11:969-75.
20. Albert J, Bjoerling E, von Gegerfelt A et al. Antigen detection is a reliable method for evaluating HIV/SIV neutralization assays. AIDS Res Hum Retroviruses 1993;9:501-4.
21. Delwart EL, Shpaer EG, Louwagie J et al. Genetic relationships determined by a DNA heteroduplex motility assay: analysis of HIV-1 env genes. Science 1993;262:1257-61.
22. Morgado MG, Guimarães ML, Neves Jr I et al. Molecular epidemiology of HIV in Brazil: polymorphism of the antigenetically distinct HIV-1 β subtype strains. Mem Inst Oswaldo Cruz 1998;93 (in press).
23. Montefiori DC, Zhou J, Barnes B et al. Homotypic antibody response to fresh clinical isolates of human immunodeficiency virus. Virology 1991;182:635-43.
24. Arendrup M, Sönnerborg A, Svennerholm B et al. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol 1993;74:855-63.
25. Björling E, Scarlatti G, von Gegerfelt A et al. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993;193:528-30.
26. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996;70:427-44.
27. Weber J, Fenyö EM, Beddows S, Kaleebu P, Björndal A, WHO Network for HIV Isolation and Characterization. Neutralization serotypes of HIV-1 field isolates are not predicted by genetic subtyping. J Virol 1996;70:7827-32.
28. Wang B, Boyer J, Srikantan V et al. DNA inoculation induces crossclade anti-HIV-1 responses. Ann N Y Acad Sci 1995;772:186-97.
29. Shibata R, Seimon C, Cho MW et al. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1. J Virol 1996;70:4361-9.
30. Nyambi PN, Willems B, Janssens W et al. The neutralization relationship of HIV-1, HIV type 2, and SIVcpz is reflected in the genetic diversity that distinguishes them. AIDS Res Hum Retrovirus 1997;13:7-17.
31. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996;70: 427-44.
32. Hendry RM, Hanson CV, Bongertz V et al. Immunoreactivity of Brazilian HIV isolates with different V3 motifs. Mem Inst Oswaldo Cruz 1996;91:347-8.
33. Bongertz V, Costa CI, Guimar̃aes ML et al. HIV specific humoral immune response in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz 1998;93 (in press).